A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytoma
Phase 1
Recruiting
- Conditions
- Surgically Resected Glioblastoma (GBM) or Astrocytoma with a Molecular Signature of Unmethylated GlioblastomaMedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10060971Term: Astrocytoma malignant Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2022-501423-25-00
- Lead Sponsor
- Curevac AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method